SEC Company Response from SPRUCE BIOSCIENCES, (SPRB) — Feb 9, 2022
SPRUCE BIOSCIENCES, INC.
Date: Feb. 9, 2022 · CIK: 0001683553 · Accession: 0001564590-22-004442
AI Filing Summary & Sentiment
File numbers found in text: 333-261960
Letter
sprb-corresp.htm
Spruce Biosciences, Inc.
2001 Junipero Serra Boulevard, Suite 640
Daly City, CA 94014
February 9, 2022
Via Edgar
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:Chris Edwards
RE:
Spruce Biosciences, Inc.
Registration Statement on Form S-3
File No. 333-261960
Acceleration Request
Requested Date:
February 11, 2022
Requested Time:
4:00 p.m. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-261960) (the “Registration Statement”) to become effective at 4:00 p.m. Eastern Time on Friday, February 11, 2022, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Alexa Ekman of Cooley LLP, counsel to the registrant, at (858) 550-6183.
[Signature page follows]
Sincerely,
Spruce Biosciences, Inc.
Show Raw Text
CORRESP 1 filename1.htm sprb-corresp.htm Spruce Biosciences, Inc. 2001 Junipero Serra Boulevard, Suite 640 Daly City, CA 94014 February 9, 2022 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn:Chris Edwards RE: Spruce Biosciences, Inc. Registration Statement on Form S-3 File No. 333-261960 Acceleration Request Requested Date: February 11, 2022 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Exchange Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-261960) (the “Registration Statement”) to become effective at 4:00 p.m. Eastern Time on Friday, February 11, 2022, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with Alexa Ekman of Cooley LLP, counsel to the registrant, at (858) 550-6183. [Signature page follows] Sincerely, Spruce Biosciences, Inc. By: /s/ Javier Szwarcberg, M.D., MPH Javier Szwarcberg, M.D., MPH Chief Executive Officer cc: Samir Gharib, President and Chief Financial Officer, Spruce Biosciences, Inc. Michael Grey, Executive Chairman, Spruce Biosciences, Inc. Alexa Ekman, Cooley LLP Daniel P. Eitutis, Cooley LLP